Highlights

• FY2026 Revenue rose 13% to $10,867 million; underlying EBITDA grew 11% to $1,933 million.

• Net profit after tax rose 17% to $621 million; Earnings Per Share grew 14% to 125.6 cents.

• Full-year Dividend reached $1.08, only fractionally ahead of the prior year's $1.07.

• The LADR Acquisition in Germany is delivering solid first-year synergies.

• Sonic completed a $445 million sale-and-leaseback of its Brisbane hub laboratory to Charter Hall.

• Operating Cash Flow rose 8% to $1,405 million.

• FY2027 guidance points to underlying EBITDA of $1,950 million to $2,030 million, with advanced diagnostics growing 15 to 16%.

Sonic Healthcare, one of the world's largest pathology and radiology providers, used its FY2026 result to remind the market that the pandemic-era distortions in diagnostics are finally behind it. Double-digit revenue growth, a lift in underlying earnings and a string of European acquisitions point to a base Business rebuilding momentum. Yet a barely changed dividend and a cautious outlook left investors debating whether growth can genuinely reaccelerate from here.

Latest Developments

For the year to 30 June 2026, Sonic reported revenue of $10,867 million, up 13 per cent, with underlying EBITDA of $1,933 million, up 11 per cent, and net profit after tax of $621 million, a 17 per cent increase. Earnings per share rose 14 per cent to 125.6 cents. The company declared a final dividend of 63 cents per share, taking the full-year payout to $1.08, only fractionally ahead of the prior year's $1.07.

Acquisitions remain central to the strategy. The integration of LADR in Germany is delivering solid first-year synergies, and Sonic monetised property through a $445 million sale-and-leaseback of its Brisbane hub laboratory to Charter Hall, alongside a conditional Sydney site sale expected to Yield a pre-tax profit of about $50 million on settlement in 2027.

What the Numbers Show

The result showed organic recovery layered on acquisitive scale. Revenue growth of 13 per cent outpaced EBITDA growth of 11 per cent, reflecting some Margin dilution from newly acquired laboratories still being integrated, while a 17 per cent lift in net profit benefited from Operating Leverage and cost discipline. Operating cash flow of $1,405 million, up 8 per cent, underpinned the Balance Sheet and the property transactions.

For FY2027, management guided to underlying EBITDA of $1,950 million to $2,030 million on a constant-currency basis, excluding around $30 million of IT transformation costs, and pointed to advanced diagnostics as a segment growing 15 to 16 per cent. The company also flagged a roughly 6 per cent increase in interest expense and an effective tax rate of about 27 per cent, both of which will temper the flow-through from EBITDA to net profit.

Geographic breadth remains both a strength and a complication. Sonic operates laboratory networks across Australia, Germany, Switzerland, the United Kingdom and the United States, so currency translation and divergent national funding regimes can materially swing the reported result even when underlying volumes are healthy.

What Could Drive the Stock Next

A US operating review is expected to deliver a $25 million to $30 million earnings benefit, and Sonic's push into advanced and molecular diagnostics offers a higher-growth adjacency to its core laboratory volumes. Continued bolt-on acquisitions in Europe, funded partly by asset recycling, could extend the earnings base.

The digital and IT transformation, while a near-term cost, is intended to lift laboratory productivity over time. How quickly these initiatives translate into margin expansion will shape whether the growth rate can step up rather than merely hold.

Key Risks to Watch

Regulatory funding pressure is a recurring theme. Swiss fee reductions carry an estimated CHF 20 million impact, and potential US PAMA fee cuts could cost around $15 million in FY2027, while integration of the UK HWE contract has been slower than planned.

The near-flat dividend and reliance on acquisitions to drive growth mean any slowdown in deal flow, or adverse currency moves given Sonic's large offshore earnings, could weigh on the Investment case.

Investor Takeaway

Sonic's FY2026 numbers confirm a diagnostics business back in growth mode, supported by disciplined Capital recycling and a clear acquisition pipeline. The debate now is one of pace: with regulatory headwinds in several markets and a dividend held broadly flat, the case for reacceleration rests on advanced diagnostics, US restructuring and the smooth digestion of recent deals.

This article is general information only and does not constitute financial or investment advice.